April 30 (Reuters) - The U.S. Food and Drug Administration (FDA) has approved granule formulation of Neurocrine Biosciences' drug to treat movement disorders associated with Huntington's disease, the company said on Tuesday. (Reporting by Sruthi Narasimha Chari and Mariam Sunny in Bengaluru; Editing by Alan Barona)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
142 USD | +0.28% | +2.14% | +7.35% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.35% | 1.43TCr | |
+8.19% | 12TCr | |
+12.82% | 11TCr | |
-13.74% | 2.23TCr | |
-3.93% | 2.16TCr | |
-6.00% | 1.82TCr | |
-39.93% | 1.76TCr | |
+33.83% | 1.24TCr | |
-27.40% | 828.11Cr | |
+17.91% | 826.08Cr |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- FDA approves Neurocrine Biosciences' Huntington's disease drug